Home » Newsletters » BioWorld Science

BioWorld Science

May 15, 2002

View Archived Issues

LidoPAIN BP effective and safe for acute lower back pain

Recent launch of new COX-2 inhibitor for acute and chronic painful conditions

U.K. launch for synthetic pentasaccharide for reducing the risk of venous thromboembolism

Broad-spectrum anticonvulsant and neuroprotective effects described for AMPA antagonist

Biochemical profile of the selective dopamine D4 receptor antagonist PD-89211

New noninvasive gene therapy approach to the treatment of osteosarcoma lung metastases

SkyePharma transfers E.U. Solaraze rights to Shire, acquires Bioglan's drug delivery business

Data analysis begins in two of aaiPharma's phase III trials for ProSorb-D

Ibandronate reduces fracture risk in postmenopausal women on different dosing regimens

Preliminary results of DAC:Opioid repeat-dose trial

AGI-1096 decreases preclinical graft narrowing associated with transplant rejection

SPP-301 enters phase II testing

CA 19-9 Radioimmunoassay approved for monitoring of pancreatic cancer

Dyax and AstraZeneca collaborate on antibody discovery and optimization

Fast track designation for Tarceva in chemotherapy-naive NSCLC

Abgenix and Corvas collaborate on therapeutic antibody development for cancer

MacroGenics licenses therapeutic target for Epstein-Barr virus

IND cleared for LymphoRad to enter phase I studies

Novel antifungal agents produced in microorganism cultures

Indazoles with thyroid hormone-like activity and their use

AstraZeneca designs new cell proliferation inhibitors targeting CDKs

New inhibitors of PDGF receptor kinase useful in cancer and other proliferative diseases

Roche presents quinoline and quinazoline NPY receptor antagonists

Japanese labs identify new antiglaucoma agents

F-15603: a new antitumor compound with apoptosis-inducing activity in p53-deficient cells

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026